stockrow
Saturday 7 November 2026
Export CLDI’s income statement to Excel — free account
Calidi Biotherapeutics, Inc.
CLDI Healthcare Biotechnology
Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00.
- EPS
- +90.8%
- Free cash flow
- +11.2%
- Total debt
- −7.87%
Quarter to June 2026, against a year earlier
0.70
0.02
+2.94%
Follow CLDI
Alert me
Calidi Biotherapeutics, Inc. (CLDI) P/E ratio
Calidi Biotherapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 106× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 106×
Ten-year median
0.0×
Current reading's percentile
84
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | n/m |
| DCOY Decoy Therapeutics Inc compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)